Rotigotine
- Generic Name
- Rotigotine
- Brand Names
- Neupro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25NOS
- CAS Number
- 99755-59-6
- Unique Ingredient Identifier
- 87T4T8BO2E
- Background
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
...
- Indication
For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01495793
- Locations
- 🇺🇸
Sp1004 012, Los Angeles, California, United States
🇺🇸Sp1004 007, West Seneca, New York, United States
🇺🇸Sp1004 013, Indianapolis, Indiana, United States
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 81
- Registration Number
- NCT01455012
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 349
- Registration Number
- NCT01300819
- Locations
- 🇧🇬
49, Sofia, Bulgaria
🇨🇭26, Sargans, Switzerland
🇨🇿222, Ostrava-Poruba, Czech Republic
Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke
- Conditions
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- University College, London
- Target Recruit Count
- 20
- Registration Number
- NCT00663338
- Locations
- 🇬🇧
Homerton University Hospital, London, United Kingdom
🇬🇧The National Hospital for Neurology & Neurosurgery, London, United Kingdom
🇬🇧Charing Cross Hospital, London, United Kingdom
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 381
- Registration Number
- NCT00599196
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 258
- Registration Number
- NCT00594386
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 217
- Registration Number
- NCT00594165
A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 14
- Registration Number
- NCT00594464
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 124
- Registration Number
- NCT00593606
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 514
- Registration Number
- NCT00522379
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.